• J. Intern. Med. · Oct 2022

    Randomized Controlled Trial Multicenter Study

    Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.

    • Mehrsa Jalalizadeh, Keini Buosi, Franciele A V Dionato, Luciana S B Dal Col, Cristiane F Giacomelli, Karen L Ferrari, Ana Carolina Pagliarone, Patrícia A F Leme, Cristiane L Maia, Reza Yadollahvandmiandoab, Quoc-Dien Trinh, Kleber G Franchini, Marcio C Bajgelman, and Leonardo O Reis.
    • Department of UroScience, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, Brazil.
    • J. Intern. Med. 2022 Oct 1; 292 (4): 654-666.

    BackgroundThe Bacillus Calmette-Guérin (BCG) vaccine may confer cross-protection against viral diseases in adults. This study evaluated BCG vaccine cross-protection in adults with convalescent coronavirus disease 2019 (COVID-19).MethodThis was a multicenter, prospective, randomized, placebo-controlled, double-blind phase III study (ClinicalTrials.gov: NCT04369794).SettingUniversity Community Health Center and Municipal Outpatient Center in South America.Patientsa total of 378 adult patients with convalescent COVID-19 were included.Interventionsingle intradermal BCG vaccine (n = 183) and placebo (n = 195).Measurementsthe primary outcome was clinical evolution. Other outcomes included adverse events and humoral immune responses for up to 6 months.ResultsA significantly higher proportion of BCG patients with anosmia and ageusia recovered at the 6-week follow-up visit than placebo (anosmia: 83.1% vs. 68.7% healed, p = 0.043, number needed to treat [NNT] = 6.9; ageusia: 81.2% vs. 63.4% healed, p = 0.032, NNT = 5.6). BCG also prevented the appearance of ageusia in the following weeks: seven in 113 (6.2%) BCG recipients versus 19 in 126 (15.1%) placebos, p = 0.036, NNT = 11.2. BCG did not induce any severe or systemic adverse effects. The most common and expected adverse effects were local vaccine lesions, erythema (n = 152; 86.4%), and papules (n = 111; 63.1%). Anti-severe acute respiratory syndrome coronavirus 2 humoral response measured by N protein immunoglobulin G titer and seroneutralization by interacting with the angiotensin-converting enzyme 2 receptor suggest that the serum of BCG-injected patients may neutralize the virus at lower specificity; however, the results were not statistically significant.ConclusionBCG vaccine is safe and offers cross-protection against COVID-19 with potential humoral response modulation.LimitationsNo severely ill patients were included.© 2022 The Association for the Publication of the Journal of Internal Medicine.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…